Tenascin-C nucleic acid ligands
First Claim
Patent Images
1. A nucleic acid ligand to tenascin-C identified according to the method comprising:
- a) contacting a candidate mixture of nucleic acids with tenascin-C, wherein nucleic acids having an increased affinity to tenascin-C relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;
b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;
c) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to tenascin-C, whereby a nucleic acid ligand of tenascin-C may be identified.
1 Assignment
0 Petitions
Accused Products
Abstract
Methods are described for the identification and preparation of nucleic acid ligands to tenascin-C. Included in the invention are specific RNA ligands to tenascin-C identified by the SELEX method. Further included in the invention are methods for detecting the presence of a disease condition in a biological tissue in which tenascin-C is expressed.
3 Citations
43 Claims
-
1. A nucleic acid ligand to tenascin-C identified according to the method comprising:
-
a) contacting a candidate mixture of nucleic acids with tenascin-C, wherein nucleic acids having an increased affinity to tenascin-C relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;
b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;
c) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to tenascin-C, whereby a nucleic acid ligand of tenascin-C may be identified. - View Dependent Claims (2, 3, 4)
-
- 5. A purified and isolated non-naturally occurring nucleic acid ligand to tenascin-C.
-
10. A method of identifying nucleic acid ligands to tenascin-C, the method comprising:
-
a) contacting a candidate mixture of nucleic acids with tenascin-C, wherein nucleic acids having an increased affinity to tenascin-C relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;
b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;
c) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to tenascin-C, whereby a nucleic acid ligand of tenascin-C may be identified. - View Dependent Claims (11, 12, 13, 14)
-
- 15. A complex for use in in vivo diagnostics comprising a tenascin-C nucleic acid ligand and a marker.
-
26. A method for the preparation of a complex comprised of a tenascin-C nucleic acid ligand and a marker, said method comprising:
-
a) contacting a candidate mixture of nucleic acids with tenascin-C, wherein nucleic acids having an increased affinity to tenascin-C relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;
b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;
c) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to tenascin-C; and
d) covalently linking said identified tenascin-C nucleic acid ligand with a marker. - View Dependent Claims (27, 28, 29, 30, 31, 32)
-
-
33. A method for detecting the presence of a disease that is expressing tenascin-C in a biological tissue which may contain said disease comprising;
-
a) identifying a nucleic acid ligand from a candidate mixture of nucleic acids, said nucleic acid ligand being a ligand of tenascin-C, by the method comprising i) contacting a candidate mixture of nucleic acids with tenascin-C, wherein nucleic acids having an increased affinity to tenascin-C relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;
ii) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;
iii) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids with relatively higher affinity and specificity for binding to tenascin-C, whereby a nucleic acid ligand of tenascin-C is identified;
b) attaching a marker that can be used in in vivo diagnostics to said nucleic acid ligand identified in step iii) to form a marker-nucleic acid ligand complex;
c) exposing a tissue which may contain said tumor to said marker-nucleic acid ligand complex; and
d) detecting the presence of said marker-nucleic acid ligand in said tissue, whereby a disease expressing tenascin-C is identified. - View Dependent Claims (34, 35, 36, 37, 38, 39, 40, 41, 42)
-
-
43. A method for delivering a therapeutic agent to a disease that is expressing tenascin-C comprising:
covalently linking a tenascin-C nucleic acid ligand with a therapeutic agent to form a complex, and administering said complex to a patient.
Specification